{"id":"ati-5923","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Dizziness"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"By inhibiting PDE9, ATI-5923 prevents the breakdown of cyclic GMP, leading to enhanced cGMP-dependent signaling pathways. This mechanism is thought to improve cognitive function and neuroplasticity. The drug is being developed for neurodegenerative and cognitive disorders where PDE9 inhibition may provide therapeutic benefit.","oneSentence":"ATI-5923 is a selective inhibitor of phosphodiesterase 9 (PDE9) that increases cyclic GMP signaling in the central nervous system.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T03:57:30.720Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Cognitive impairment associated with schizophrenia"},{"name":"Alzheimer's disease"}]},"trialDetails":[{"nctId":"NCT04627116","phase":"PHASE1","title":"An Ascending, Multiple-Dose, Safety and Tolerability Study of Tecarfarin in Healthy Chinese Volunteers","status":"UNKNOWN","sponsor":"Lee's Pharmaceutical Limited","startDate":"2020-04-19","conditions":"Healthy Chinese Volunteers","enrollment":40},{"nctId":"NCT03652779","phase":"PHASE1","title":"A Study to Evaluate the Safety and Tolerability of Tecarfarin in Healthy Chinese Volunteers","status":"COMPLETED","sponsor":"Lee's Pharmaceutical Limited","startDate":"2018-06-22","conditions":"Pharmacokinetic and Pharmacodynamic Profile of Tecarfarin","enrollment":40},{"nctId":"NCT02522221","phase":"PHASE3","title":"Tecarfarin Anti-Coagulation Trial (TACT)","status":"UNKNOWN","sponsor":"Espero Biopharma","startDate":"2018-06-01","conditions":"Thromboembolism, Thrombosis","enrollment":1000},{"nctId":"NCT00691470","phase":"PHASE2, PHASE3","title":"Comparison of ATI-5923, a Novel Vitamin K Antagonist, With Warfarin in Patients Requiring Chronic Anticoagulation","status":"UNKNOWN","sponsor":"ARYx Therapeutics","startDate":"2008-05","conditions":"Atrial Fibrillation, Atrial Flutter, Venous Thromboembolic Disease","enrollment":600},{"nctId":"NCT00431782","phase":"PHASE2","title":"Study of a New Anticoagulant Drug in Patients With Atrial Fibrillation","status":"COMPLETED","sponsor":"ARYx Therapeutics","startDate":"2006-12","conditions":"Atrial Fibrillation","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"ATI-5923","genericName":"ATI-5923","companyName":"ARYx Therapeutics","companyId":"aryx-therapeutics","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ATI-5923 is a selective inhibitor of phosphodiesterase 9 (PDE9) that increases cyclic GMP signaling in the central nervous system. Used for Cognitive impairment associated with schizophrenia, Alzheimer's disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}